1. Home
  2. ULY vs KALA Comparison

ULY vs KALA Comparison

Compare ULY & KALA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Urgent.ly Inc.

ULY

Urgent.ly Inc.

HOLD

Current Price

$2.46

Market Cap

5.5M

Sector

N/A

ML Signal

HOLD

Logo KALA BIO Inc.

KALA

KALA BIO Inc.

HOLD

Current Price

$0.60

Market Cap

6.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ULY
KALA
Founded
2013
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.5M
6.0M
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
ULY
KALA
Price
$2.46
$0.60
Analyst Decision
Strong Buy
Buy
Analyst Count
2
3
Target Price
$11.50
$31.50
AVG Volume (30 Days)
1.5M
2.3M
Earning Date
03-11-2026
11-19-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$127,932,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$18.95
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.74
$0.51
52 Week High
$17.99
$20.60

Technical Indicators

Market Signals
Indicator
ULY
KALA
Relative Strength Index (RSI) 46.53 41.95
Support Level $2.12 $0.58
Resistance Level $2.75 $0.71
Average True Range (ATR) 0.35 0.05
MACD -0.07 0.02
Stochastic Oscillator 15.13 11.92

Price Performance

Historical Comparison
ULY
KALA

About ULY Urgent.ly Inc.

Urgently Inc is a connected mobility assistance software platform, matching vehicle owners and operators with service professionals who deliver traditional roadside assistance, proactive maintenance and repair services. The traditional experience of a vehicle breakdown is often stressful and inconvenient, compounded by processes that lack transparency and to long wait times. Urgently offers an alternative to this traditional experience, leveraging its digitally native software platform to match supply and demand in its network and deliver exceptional mobility assistance experiences at scale.

About KALA KALA BIO Inc.

Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.

Share on Social Networks: